BR112022014020A2 - Derivado de isoindolina e composição farmacêutica e uso do mesmo - Google Patents

Derivado de isoindolina e composição farmacêutica e uso do mesmo

Info

Publication number
BR112022014020A2
BR112022014020A2 BR112022014020A BR112022014020A BR112022014020A2 BR 112022014020 A2 BR112022014020 A2 BR 112022014020A2 BR 112022014020 A BR112022014020 A BR 112022014020A BR 112022014020 A BR112022014020 A BR 112022014020A BR 112022014020 A2 BR112022014020 A2 BR 112022014020A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
isoindoline derivative
isoindoline
derivative
cereblon
Prior art date
Application number
BR112022014020A
Other languages
English (en)
Inventor
Liu Hui
Deng Yanjun
Ge Chuansheng
Zhang Lei
Xing Feng
Original Assignee
Kangpu Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kangpu Biopharmaceuticals Ltd filed Critical Kangpu Biopharmaceuticals Ltd
Publication of BR112022014020A2 publication Critical patent/BR112022014020A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADO DE ISOINDOLINA E COMPOSIÇÃO FARMACÊUTICA E USO DO MESMO. São divulgados um derivado de isoindolina, um intermediário do mesmo, um método de preparação do mesmo, uma composição farmacêutica do mesmo e seu uso. Os derivados de isoindolina da presente invenção podem visar e regular especificamente várias proteínas ao se ligarem ao Cereblon, tratando assim eficazmente cânceres e outras doenças relacionadas.
BR112022014020A 2020-01-20 2021-01-20 Derivado de isoindolina e composição farmacêutica e uso do mesmo BR112022014020A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010067409 2020-01-20
CN202010413162 2020-05-15
PCT/CN2021/072840 WO2021147889A1 (zh) 2020-01-20 2021-01-20 一种异吲哚啉衍生物、其药物组合物及应用

Publications (1)

Publication Number Publication Date
BR112022014020A2 true BR112022014020A2 (pt) 2022-10-11

Family

ID=76992033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014020A BR112022014020A2 (pt) 2020-01-20 2021-01-20 Derivado de isoindolina e composição farmacêutica e uso do mesmo

Country Status (9)

Country Link
US (1) US20230114674A1 (pt)
JP (1) JP7408819B2 (pt)
KR (1) KR20220124228A (pt)
CN (1) CN115038694A (pt)
AU (1) AU2021209727B2 (pt)
BR (1) BR112022014020A2 (pt)
CA (1) CA3168456A1 (pt)
WO (1) WO2021147889A1 (pt)
ZA (1) ZA202209293B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122615A1 (en) * 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN115197084A (zh) * 2022-07-11 2022-10-18 中国船舶重工集团公司第七一八研究所 一种恩杂鲁胺关键中间体的制备方法
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3599236B1 (en) * 2010-02-11 2023-08-23 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
AU2015341301B2 (en) * 2014-10-30 2019-05-16 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
CA3041284A1 (en) * 2016-10-20 2018-04-26 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
TWI830576B (zh) * 2017-07-10 2024-01-21 美商西建公司 抗增生化合物及其使用方法
EP4272737A3 (en) * 2018-04-23 2024-01-17 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
HRP20230449T1 (hr) * 2018-05-23 2023-07-21 Celgene Corporation Antiproliferativni spojevi i bispecifična protutijela protiv bcma i cd3 za kombiniranu upotrebu
CA3101174A1 (en) * 2018-05-23 2019-11-28 Celgene Corporation Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
CA3125756A1 (en) * 2019-01-09 2020-07-16 Celgene Corporation Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same

Also Published As

Publication number Publication date
EP4095132A1 (en) 2022-11-30
KR20220124228A (ko) 2022-09-13
CA3168456A1 (en) 2021-07-29
US20230114674A1 (en) 2023-04-13
CN115038694A (zh) 2022-09-09
JP2023511146A (ja) 2023-03-16
JP7408819B2 (ja) 2024-01-05
AU2021209727B2 (en) 2024-01-11
AU2021209727A1 (en) 2022-09-15
WO2021147889A1 (zh) 2021-07-29
ZA202209293B (en) 2023-05-31

Similar Documents

Publication Publication Date Title
BR112022014020A2 (pt) Derivado de isoindolina e composição farmacêutica e uso do mesmo
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112023019797A2 (pt) Inibidor derivado heterocíclico e método de preparação do mesmo e aplicação do mesmo
MX2022001302A (es) Inhibidores de kif18a.
BR112021025034A2 (pt) Imunoconjugado, composto aminobenzazepina-ligante, composição farmacêutica, métodos para tratar câncer e para preparar um imunoconjugado e uso de um imunoconjugado
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
BR112021023229A2 (pt) Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso
BRPI1008145B8 (pt) Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica
BR112021017049A2 (pt) Derivados de tiazol como inibidores de secreção de proteínas
BR112022019020A2 (pt) Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas
BR112016028835A2 (pt) derivados de auristatina e conjugados dos mesmos
BR112021025928A2 (pt) Métodos de preparação de ácido bempedoico e composições do mesmo
BR112016008593A8 (pt) composto, composição farmacêutica, método de regulação de transcrição gênica em uma célula, uso de um composto e método de inibição de reconhecimento mediado por bromodomínio de uma região de acetil lisina de uma proteína
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BRPI0709680B8 (pt) derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase
BRPI0513858A (pt) compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa
BRPI0508144A (pt) derivados de oligossacarìdeos sulfatados composto da fórmula geral; composição farmacêutica ou veterinária seu uso; método para a prevenção ou tratamento pelo uso da mesma
BR112022007719A2 (pt) Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado
BR112018010394A8 (pt) anticorpo, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação do anticorpo.
BR112017010645A2 (pt) derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos
BR112021018924A2 (pt) Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
BR112021017415A2 (pt) Derivados de pirimidona de anel fundido para uso no tratamento de infecção por vhb ou de doenças induzidas por vhb
BR112021021224A2 (pt) Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
AU2018341781A8 (en) Fused ring derivative as A2A receptor inhibitor

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]